Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.39 |
| ▸ | HTR2C | P28335 | 12/20 | 0.39 |
| ▸ | HTR2B | P41595 | 12/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6110760 | 0.74 | HTR2C (0.38) | HTR2AHTR2CHTR2BPLD1CYP2D6 | |
| SCHEMBL31232802 | 0.73 | PLD1 (0.42) | HTR2AHTR2CHTR2BPLD1ALDH1A1 | |
| SCHEMBL2900748 | 0.73 | PLD1 (0.42) | HTR2AHTR2CHTR2BPLD1ALDH1A1 | |
| SCHEMBL12807031 | 0.72 | SLC6A2 (0.49) | HTR2AHTR2CHTR2BPLD1CYP2D6 | |
| SCHEMBL16053272 | 0.72 | HTR3A (0.41) | HTR2AHTR2CHTR2BCYP2D6SLC6A2 | |
| SCHEMBL24352612 | 0.71 | HTR3A (0.41) | HTR2AHTR2CHTR2BPLD1CYP2D6 | |
| SCHEMBL20993629 | 0.71 | HTR3A (0.41) | HTR2AHTR2CHTR2BPLD1CYP2D6 | |
| SCHEMBL20993537 | 0.71 | HTR3A (0.41) | HTR2AHTR2CHTR2BPLD1CYP2D6 | |
| SCHEMBL27911852 | 0.71 | HTT (0.47) | HTR2AHTR2CHTR2BALDH1A1SIGMAR1 | |
| SCHEMBL16500313 | 0.70 | ADRB1 (0.46) | HTR2AHTR2CHTR2BCYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096305-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| WO-2011159794-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096305-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | VCAM1, CD4, ICAM1 | HTR2A 2107/4885HTR2C 1870/4885HTR2B 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.